Summary
Danaher Corporation reported solid financial results for the first quarter of 2022, demonstrating resilience amidst global economic uncertainties. Total revenues grew by 12.0% year-over-year, driven by a robust 12.0% increase in core sales, indicating strong performance in existing business operations. This growth was seen across both developed and high-growth markets, with developed markets experiencing over 15% growth, primarily in North America and Western Europe. High-growth markets saw low-single-digit growth, though this was impacted by COVID-19 related shutdowns in China and a difficult comparison to the prior year's major project completion in the region. Net earnings attributable to common stockholders rose to $1,684 million, or $2.31 per diluted share, from $1,661 million, or $2.29 per diluted share, in the prior year's period. This increase was largely attributed to higher core sales, though partially offset by foreign currency headwinds, Russia-related charges, and increased material, transportation, and labor costs. The company also provided an update on its strategic priorities, including continued investment in organic growth and acquisitions, and highlighted its strong liquidity position with approximately $3.7 billion in cash and cash equivalents as of April 1, 2022, positioning it to navigate current challenges and pursue future opportunities.
Financial Highlights
50 data points| Revenue | $6.53B |
| Cost of Revenue | $2.98B |
| Gross Profit | $4.06B |
| R&D Expenses | $441.00M |
| SG&A Expenses | $2.09B |
| Operating Income | $1.93B |
| Interest Expense | $54.00M |
| Net Income | $1.68B |
| EPS (Basic) | $2.35 |
| EPS (Diluted) | $2.31 |
| Shares Outstanding (Basic) | 716.30M |
| Shares Outstanding (Diluted) | 737.70M |
Key Highlights
- 1Total revenue increased by 12.0% year-over-year to $7,688 million, driven by a 12.0% rise in core sales.
- 2Net earnings attributable to common stockholders were $1,684 million ($2.31 per diluted share), up from $1,661 million ($2.29 per diluted share) in the prior year's quarter.
- 3The Diagnostics segment showed significant strength with core sales growth of 22.5%, driven by strong demand for molecular diagnostics, including COVID-19 tests.
- 4The Life Sciences segment reported core sales growth of 7.5%, supported by demand in bioprocess and filtration/separation technologies, though some areas like flow cytometry experienced lower demand.
- 5The Environmental & Applied Solutions segment achieved core sales growth of 6.5%, with solid performance in water quality and product identification businesses.
- 6Danaher incurred a $43 million pretax charge related to its Russian operations, primarily due to asset impairments and contractual obligations, suspending most product shipments to Russia except for critical medical needs.
- 7The company maintained a strong liquidity position with $3.7 billion in cash and cash equivalents as of April 1, 2022, and substantial operating cash flows of $1.97 billion for the quarter.